Clinical and laboratory manifestations associated to IL-17 in childhood-onset systemic lupus erythematosus

Author(s)

Karina de Oliveira Peliçari

• Document type: Master's Dissertation
• Press: Campinas, SP.
• Institution: Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas
• Defense date: 2013-04-02

Examining board members

Simone Appenzeller; Manoel Barros Bértolo; Virginia Paes Leme Ferriani

• Advisor: Simone Appenzeller; Roberto Marini; Lilian Tereza Lavras Costallat

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisistemic autoimmune disease, , characterized by periods of activity and remission. Haematological and immunological abnormalities are commonly observed. Laboratory evaluation, including the cytokine profile, aids in the diagnosis and determination of disease activity. The present transverse study, we aimed to evaluate levels of IL-17 in patients with childhood-onset SLE (cSLE) (disease onset ? 16 years), first-degree relatives and healthy controls and to determine the association between IL-17 levels and disease activity, laboratory data and treatment. We selected consecutive patients with cSLE followed at the Pediatric Rheumatology Unit at UNICAMP between 2009/2011. Clinical, laboratory, disease activity [SLE Disease Activity Index (SLEDAI)], cumulative damage [Systemic Lupus International Collaborating Clinics / American College of Rheumatology Damage Index (SDI)] and medication use were assessed. Mood disorders were measured using the Beck's Depression Inventory (BDI) and Anxiety Inventory (BAI). Determination of cytokine levels was carried out by ELISA. Serum levels of IL-17 were increased in SLE (p ? 0.05) when compared to healthy controls. An association was observed between serum IL-17 levels and migraine (p = 0.03) and nephritis (p = 0.01). IL-17 levels were not associated with disease activity (p = 0.32), cumulative damage (p = 0.34), medication (p = 0.63), anxiety (p = 0.42) and depression (p = 0.42). Longitudinal studies are needed to determine if serum IL-17 levels can be used as a biomarker in SLE (AU)

• FAPESP's process: 10/13636-2 - Clinical and laboratory findings associated with IL - 17 in systemic lupus erythematosus
• Grantee: Karina de Oliveira Peliçari
• Support Opportunities: Scholarships in Brazil - Master